STOCK TITAN

Cardiff Oncology Phase 3 trial may start in Q1 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Cardiff Oncology, Inc. (CRDF) reported third-quarter 2026 results and said its randomized Phase 2 trial of onvansertib plus FOLFIRI/bev for first-line RAS-mutated metastatic colorectal cancer remains ongoing. Median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, versus approximately 11 months in the combined standard-of-care arms. As of September 28, 2026, 6 patients remained on FOLFIRI/bev regimens; all patients remaining in the 30 mg arm had exceeded 21 months on treatment, with the longest duration exceeding 29 months. Cardiff is preparing a registrational Phase 3 trial, with a potential start in Q1 2027.

As of September 30, 2026, cash, cash equivalents and short-term investments totaled approximately $33.8 million. Cardiff believes its current cash resources are sufficient to fund operations to the end of the third quarter of 2027, based on current expectations and projections. Nine-month operating cash use was approximately $33.9 million, compared with $31.9 million in 2025. Nine-month operating expenses were $32.0 million versus $41.5 million, and net loss was $30.4 million versus $38.6 million. Royalty revenue was $171,000 for the quarter versus $120,000 in 2025, and $316,000 for nine months versus $350,000.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month net loss narrowed to $30.4 million from $38.6 million.
  • Minor pointQuarterly royalty revenue rose to $171,000 from $120,000.

Negative

  • Moderate pointNine-month operating cash use increased to $33.9 million from $31.9 million.
  • Minor pointNine-month royalty revenue declined to $316,000 from $350,000.

Filing Explained

Cardiff completed a July 2026 offering of common stock and warrants, raising $9.1 million net; the share issuance increases the share count and reduces existing holders’ ownership percentages, but the filing provides no share or warrant quantities to size that dilution.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and short-term investments Approximately $33.8 million As of September 30, 2026.
Cash runway Through the end of the third quarter of 2027 Cardiff's estimate based on current expectations and projections.
Net cash used in operating activities Approximately $33.9 million Nine months ended September 30, 2026; compared with $31.9 million in 2025.
Total operating expenses $32.0 million Nine months ended September 30, 2026; compared with $41.5 million in 2025.
Net loss $30.4 million Nine months ended September 30, 2026; compared with $38.6 million in 2025.
Royalty revenue $171,000 Three months ended September 30, 2026; compared with $120,000 in 2025.
Royalty revenue $316,000 Nine months ended September 30, 2026; compared with $350,000 in 2025.
Median PFS Not reached in the 30 mg onvansertib + FOLFIRI/bev arm; approximately 11 months in the combined standard-of-care arms Ongoing randomized Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer.
progression-free survival (“PFS”) medical
"Median progression-free survival (“PFS”) has not been reached"
FOLFIRI/bev medical
"30 mg onvansertib + FOLFIRI/bev arm"
standard-of-care (“SoC”) medical
"combined SoC arms"
PLK1 inhibition medical
"focused on PLK1 inhibition"
PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.
RAS-mutated mCRC medical
"first-line RAS-mutated mCRC"
chemistry, manufacturing and controls (“CMC”) technical
"completion of chemistry, manufacturing and controls (“CMC”) activities"
Royalty revenue, three months $171,000 Compared with $120,000 in 2025
Net loss, three months $8.857 million Compared with $11.258 million in 2025
Total operating expenses, nine months $32.0 million Compared with $41.5 million in 2025
Net loss, nine months $30.4 million Compared with $38.6 million in 2025
Royalty revenue, nine months $316,000 Compared with $350,000 in 2025
Guidance

Based on current expectations and projections, Cardiff believes its current cash resources are sufficient to fund operations to the end of the third quarter of 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRDF report about its Phase 2 trial?

Median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, while median PFS in the combined standard-of-care arms was approximately 11 months. As of September 28, 2026, 6 patients remained on FOLFIRI/bev regimens: 5 in onvansertib arms and 1 in the standard-of-care arm.

What were Cardiff Oncology's third-quarter 2026 financial results?

For the three months ended September 30, 2026, royalty revenue was $171,000 and net loss was $8.857 million, compared with $120,000 in revenue and an $11.258 million net loss in 2025. For the nine months, royalty revenue was $316,000 and net loss was $30.4 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001213037false00012130372026-11-102026-11-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

 

 

Cardiff Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35558

27-2004382

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11055 Flintkote Avenue

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 952-7570

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

CRDF

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

On November 12, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press Release of Cardiff Oncology, Inc. dated November 12, 2026

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CARDIFF ONCOLOGY, INC.

 

 

 

 

Date:

November 12, 2026

By:

/s/ Mani Mohindru

 

 

 

Mani Mohindru

President and Chief Executive Officer

 


 

 

img186708884_0.jpg

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

 

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

 

 

All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatment

 

 

Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027

 

SAN DIEGO, Calif., November 12, 2026 — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”

Clinical Highlights

 

Randomized Phase 2 Trial in First-Line RAS-Mutated Metastatic Colorectal Cancer (“mCRC”) Ongoing

 

Cardiff’s randomized Phase 2 trial evaluating onvansertib in combination with FOLFIRI/ bevacizumab (“bev”) or FOLFOX/bev as first-line therapy in patients with RAS-mutated mCRC remains ongoing. Median progression-free survival (“PFS”) has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the Company’s proposed Phase 3 regimen.

 

As of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen, with 5 patients in the onvansertib (20 or 30 mg) + FOLFIRI/bev arms and 1 patient on standard-of-care (“SoC”) FOLFIRI/bev. Patients who remain in the 30 mg onvansertib + FOLFIRI/bev arm have been on treatment for at least 21 months, with the longest duration of treatment being over 29 months.

 

For comparison, the median PFS in the combined SoC arms has been reached at approximately 11 months, consistent with what has been historically reported.

 

 


 

 

 

Corporate Updates

·
In July, Cardiff completed a $10 million registered direct offering of common stock and warrants to support working capital and general corporate purposes. The full press release is available here.
·
In September, Cardiff and its licensor, Nerviano Medical Sciences S.r.l. (“NMS”), resolved all outstanding disputes regarding global rights to onvansertib and amended their 2017 exclusive license agreement. The full press release is available here.
·
In October, Cardiff appointed Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned oncology executive who has served as Chief Medical Officer at several clinical-stage biotechnology companies and previously held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approval of multiple oncology therapies. The full press release is available here.

 

Upcoming Events

·
Cardiff management will present at the UBS Global Biopharma Conference and participate in one-on-one investor meetings on November 16–17, 2026. Dr. Mohindru’s presentation is scheduled for November 16 at 2:40 p.m. GMT. A live webcast and replay will be available in the “Events” section of the Cardiff Oncology website.
·
Updated data from an investigator-sponsored clinical trial in CMML will be presented at the American Society of Hematology (“ASH”) Annual Meeting on December 13, 2026.

 

Third Quarter 2026 Financial Results

 

Liquidity, cash burn, and cash runway

 

As of September 30, 2026, Cardiff Oncology had approximately $33.8 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $33.9 million, an increase of $2.0 million from $31.9 million for the same period in 2025. In July 2026, the Company raised net proceeds of approximately $9.1 million in a registered direct offering. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations to the end of the third quarter of 2027.

 

Operating results

 

Total operating expenses were approximately $32.0 million for the nine months ended September 30, 2026, a decrease of $9.5 million from $41.5 million for the same period in 2025. R&D expenses decreased by $12.5 million, reflecting the completion of clinical trials, fewer patients on treatment in the Phase 2 mCRC trial, a reduction in preclinical activities, and completion of chemistry, manufacturing and controls (“CMC”) activities as the Company prepares for its planned Phase 3 mCRC trial. SG&A expenses increased by $3.1 million, driven by legal and professional fees related to the Company’s dispute with NMS, which was resolved on September 14, 2026, and also by employee severance costs. Net loss was $30.4 million, compared with $38.6 million for the prior year period.

 

About Cardiff Oncology, Inc.

 


 

 

Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially.

There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, uncertainties associated with clinical development and regulatory approvals; the possibility that results from earlier clinical studies may not be predictive of future results; risks related to the timing, initiation, conduct and completion of clinical trials; the Company's need for additional financing; dependence on key personnel and third parties; competition; intellectual property risks; and other factors described in Cardiff Oncology's filings with the Securities and Exchange Commission. There can be no assurance that onvansertib will receive regulatory approval for any indication or prove commercially successful.

Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

 

Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

 


 

Cardiff Oncology, Inc.

Condensed Statements of Operations

(in thousands, except for per share amounts)

(unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Royalty revenues

 

$

171

 

 

$

120

 

 

$

316

 

 

$

350

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

5,029

 

 

 

8,197

 

 

 

17,709

 

 

 

30,254

 

Selling, general and administrative

 

 

4,361

 

 

 

3,897

 

 

 

14,291

 

 

 

11,229

 

Total operating expenses

 

 

9,390

 

 

 

12,094

 

 

 

32,000

 

 

 

41,483

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(9,219

)

 

 

(11,974

)

 

 

(31,684

)

 

 

(41,133

)

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

363

 

 

 

716

 

 

 

1,251

 

 

 

2,492

 

Other income (expense), net

 

 

(1

)

 

 

0

 

 

 

(1

)

 

 

6

 

Total other income (expense), net

 

 

362

 

 

 

716

 

 

 

1,250

 

 

 

2,498

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(8,857

)

 

 

(11,258

)

 

 

(30,434

)

 

 

(38,635

)

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock dividend

 

 

(6

)

 

 

(6

)

 

 

(18

)

 

 

(18

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(8,863

)

 

$

(11,264

)

 

$

(30,452

)

 

$

(38,653

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share — basic and diluted

 

$

(0.12

)

 

$

(0.17

)

 

$

(0.43

)

 

$

(0.58

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding — basic
   and diluted

 

 

76,178

 

 

 

66,879

 

 

 

71,004

 

 

 

66,644

 

 

 


 

Cardiff Oncology, Inc.

Condensed Balance Sheets

(in thousands)

(unaudited)

 

 

September 30,
2026

 

 

December 31,
2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,060

 

 

$

17,470

 

Short-term investments

 

 

21,730

 

 

 

40,834

 

Accounts receivable and unbilled receivable

 

 

90

 

 

 

182

 

Prepaid expenses and other current assets

 

 

1,146

 

 

 

1,642

 

Total current assets

 

 

35,026

 

 

 

60,128

 

Property and equipment, net

 

 

364

 

 

 

578

 

Operating lease right-of-use assets

 

 

225

 

 

 

629

 

Other assets

 

 

799

 

 

 

549

 

Total Assets

 

$

36,414

 

 

$

61,884

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

693

 

 

$

8,087

 

Accrued liabilities

 

 

7,358

 

 

 

7,577

 

Operating lease liabilities

 

 

265

 

 

 

730

 

Total current liabilities

 

 

8,316

 

 

 

16,394

 

Operating lease liabilities, net of current portion

 

 

—

 

 

 

102

 

Total Liabilities

 

 

8,316

 

 

 

16,496

 

 

 

 

 

 

 

Stockholders’ equity

 

 

28,098

 

 

 

45,388

 

Total liabilities and stockholders’ equity

 

$

36,414

 

 

$

61,884

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading